Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Transplant patients are particularly at a higher risk of contracting COVID-19 because of their immunosuppressed state, and they have the propensity to develop opportunistic infections. The pre-immunosuppressed state, along with other existing comorbidities, can influence the outcomes of COVID-19 in transplant patients. We describe a case of a renal transplant patient who developed COVID-19. Real-time nucleic acid testing (NAT) should be done in deceased and living donors. The most common management strategy is the modification of immunosuppression along with current experimental strategies for COVID-19.
All Keywords
【저자키워드】 COVID-19, coronavirus, acute respiratory distress syndrome, Renal transplant, 【초록키워드】 Coronavirus disease 2019, Comorbidities, Immunosuppression, outcome, nucleic acid, Transplant, management, Patient, morbidity and mortality, donors, patients, opportunistic Infections, Deceased, Immunosuppressed, higher risk, renal, Modification, develop, 【제목키워드】 Transplant,
【저자키워드】 COVID-19, coronavirus, acute respiratory distress syndrome, Renal transplant, 【초록키워드】 Coronavirus disease 2019, Comorbidities, Immunosuppression, outcome, nucleic acid, Transplant, management, Patient, morbidity and mortality, donors, patients, opportunistic Infections, Deceased, Immunosuppressed, higher risk, renal, Modification, develop, 【제목키워드】 Transplant,